Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Dexmedetomidine and Melatonin for Sleep Induction for EEG in Children (MeloDex)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04665453
Recruitment Status : Recruiting
First Posted : December 11, 2020
Last Update Posted : December 16, 2020
Sponsor:
Information provided by (Responsible Party):
Damjan Osredkar, University Medical Centre Ljubljana

Brief Summary:
The aim of the study is to compare the effect of melatonin, given orally, dexmedetomidine, given intranasally, and dexmedetomidine given sublingually on sleep induction, sleep duration, their possible impact on vital functions and technical implementation of EEG.

Condition or disease Intervention/treatment Phase
Electroencephalography Child Dexmedetomidine Melatonin Sleep Epilepsy Diagnostic Test: Electroencephalography Diagnostic Test: Monitoring of vital functions Drug: Melatonin 0,1mg/kg oral syrup Drug: Dexmedetomidine 3 mcg/kg sublingually Drug: Dexmedetomidine 3 mcg/kg intranasally Not Applicable

Detailed Description:

At University Medical Centre Ljubljana (UMCL; Slovenia), the investigators use electroencephalography (EEG) in wakefulness and sleep for diagnostic and therapeutic purposes in children with (suspected) epilepsy. Since epileptiform activity can only be detected during sleep in some patients and because children with intellectual disabilities have sometimes problems with cooperation, EEG in induced sleep is required.

In this study, the investigators will enroll 150 children who need EEG recorded in their sleep. The investigators will compare safety and efficacy of the two active substances, one of which will be given in two possible routes. Fifty children will receive melatonin in the form of a syrup orally, 50 children will receive dexmedetomidine intranasally in the form of a nasal spray, and 50 children will receive dexmedetomidine sublingually. The investigators will monitor the following parameters: the time in which the child falls asleep, vital functions during sleep (blood pressure, blood oxygen saturation, respiratory rate frequency and heart rate frequency), the impact on the technical implementation of EEG, the depth of sleep and waking time. All parents will give their written consent for their child to participate in the study.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 150 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic
Official Title: Comparison of Efficacy of Dexmedetomidine and Melatonin for Sleep Induction for Electroencephalography in Children
Actual Study Start Date : September 1, 2020
Estimated Primary Completion Date : December 31, 2021
Estimated Study Completion Date : December 31, 2021

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Melatonin peroral
0,1mg/kg melatonin will be given in the form of a syrup to the participant before EEG and vital functions monitoring
Diagnostic Test: Electroencephalography
Recording of the brain electrical activity during sleep; background activity and sleep phases will be evaluated
Other Name: EEG

Diagnostic Test: Monitoring of vital functions
Measuring of respiratory rate, heart rate, SpO2, every 10 minutes after the medicine is given to the patient for the duration of EEG, and after 120 minutes. Blood pressure is measured at the time of application of the medicine, at the end of EEG and after 120 minutes.

Drug: Melatonin 0,1mg/kg oral syrup
Melatonine in the form of syrup will be given orally to child.

Experimental: Dexmedetomidine intranasally
3 mcg/kg of dexmedetomidine in the form of a nasal spray will be given to the participant before EEG and vital functions monitoring
Diagnostic Test: Electroencephalography
Recording of the brain electrical activity during sleep; background activity and sleep phases will be evaluated
Other Name: EEG

Diagnostic Test: Monitoring of vital functions
Measuring of respiratory rate, heart rate, SpO2, every 10 minutes after the medicine is given to the patient for the duration of EEG, and after 120 minutes. Blood pressure is measured at the time of application of the medicine, at the end of EEG and after 120 minutes.

Drug: Dexmedetomidine 3 mcg/kg intranasally
Dexmedetomidine in the form of nasal spray will be given to child intranasally.

Experimental: Dexmedetomidine sublingually
3 mcg/kg of dexmedetomidine will be given to the participant sublingually before EEG and vital functions monitoring
Diagnostic Test: Electroencephalography
Recording of the brain electrical activity during sleep; background activity and sleep phases will be evaluated
Other Name: EEG

Diagnostic Test: Monitoring of vital functions
Measuring of respiratory rate, heart rate, SpO2, every 10 minutes after the medicine is given to the patient for the duration of EEG, and after 120 minutes. Blood pressure is measured at the time of application of the medicine, at the end of EEG and after 120 minutes.

Drug: Dexmedetomidine 3 mcg/kg sublingually
Dexmedetomidine in the form of a solution will be given to child sublingually.




Primary Outcome Measures :
  1. Comparison of the three medical interventions on sleep initiation [ Time Frame: During the intervention ]
    The time-interval between the drug application and time of sleep initiation will be recorded in minutes. These values will be compared across the three arms of the study

  2. Comparison of the three medical interventions on the depth of sleep and the most prominent sleep stage on EEG [ Time Frame: During the intervention ]
    During EEG in sleep, which will be recorderd using a standard 10-20 placement with additional electrodes for breathing and ECG, the EEG background activity will be evaluated for the deepest sleep stage according to the standard EEG classification (Carskadon MA, Dement WC. Normal Human Sleep: an Overview. In: Kryger M, Roth T, Dement WC. Principles and practice of sleep medicine. St.Louis: Saunders/Elsevier, 2011:16-26.). Also, the sleep stage in which the patient will spend the most time will be noted. These values will be compared across the three arms of the study.


Secondary Outcome Measures :
  1. Comparison of the three medical interventions on respiratory rate [ Time Frame: During the intervention ]
    Measurement of respiratory rate every 10 minutes after the medicine is given to the patient for the duration of EEG recording, and after 120 minutes. The values will be compared across the three arms of the study.

  2. Comparison of the three medical interventions on heart rate [ Time Frame: During the intervention ]
    Measurement of heart rate every 10 minutes after the medicine is given to the patient for the duration of EEG recording, and after 120 minutes. The values will be compared across the three arms of the study.

  3. Comparison of the three medical interventions on oxygene saturation [ Time Frame: During the intervention ]
    Measurement of oxygene saturation using pulse oximetry every 10 minutes after the medicine is given to the patient for the duration of EEG recording, and after 120 minutes. The values will be compared across the three arms of the study.

  4. Comparison of the three medical interventions on blood pressure [ Time Frame: During the intervention ]
    Measurement of systolic and diastolic blood pressure will be noted at the time of application of the medicine, at the end of EEG and after 120 minutes. These values will be compared across the three arms of the study.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   1 Year to 20 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Age between 1 and 20 years
  • Referral for EEG in sleep
  • Children/young adults whose parents/caregivers were informed about the aims of the study and have signed the Informed consent form

Exclusion Criteria:

  • Children that were unable to follow the study protocol were excluded during the study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04665453


Contacts
Layout table for location contacts
Contact: Damjan Osredkar, MD, PhD 0038615229273 damjan.osredkar@kclj.si
Contact: Urška Mahne, MD, BVetMed 0038615229273 urskamahne@yahoo.co.uk

Locations
Layout table for location information
Slovenia
University Medical Centre Ljubljana Recruiting
Ljubljana, Slovenia, 1000
Contact: Damjan Osredkar, MD, PhD       damjan.osredkar@kclj.si   
Contact: Urška Mahne, MD, BVetMed.       urskamahne@yahoo.co.uk   
Sub-Investigator: Urška Mahne, MD, BVetMed         
Sub-Investigator: Eva Vrščaj, MD         
Sub-Investigator: Katja Peganc, OT         
Sub-Investigator: David Neubauer, MD, PhD         
Sub-Investigator: Mirjana Perković Benedik, MD, PhD         
Sub-Investigator: Neli Bizjak, MD, PhD         
Sub-Investigator: Zvonka Rener Primec, MD, PhD         
Sub-Investigator: Jasna Oražem, MD         
Sub-Investigator: Tita Butenko, MD         
Sub-Investigator: Nataša Šuštar, MD         
Principal Investigator: Damjan Osredkar, MD, PhD         
Sub-Investigator: Eva Rihar, MD         
Sponsors and Collaborators
University Medical Centre Ljubljana
Layout table for additonal information
Responsible Party: Damjan Osredkar, Assoc. Prof. Damjan Osredkar, MD, PhD, University Medical Centre Ljubljana
ClinicalTrials.gov Identifier: NCT04665453    
Other Study ID Numbers: 0120-597/2019/16
First Posted: December 11, 2020    Key Record Dates
Last Update Posted: December 16, 2020
Last Verified: December 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Keywords provided by Damjan Osredkar, University Medical Centre Ljubljana:
Child
Dexmedetomidine
Melatonin
Electroencephalography
Autism Spectrum Disorder
Developmental Delay Disorder
Epilepsy
Sleep
Sleep induction
Additional relevant MeSH terms:
Layout table for MeSH terms
Epilepsy
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Dexmedetomidine
Melatonin
Hypnotics and Sedatives
Central Nervous System Depressants
Physiological Effects of Drugs
Analgesics, Non-Narcotic
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Adrenergic alpha-2 Receptor Agonists
Adrenergic alpha-Agonists
Adrenergic Agonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Antioxidants
Protective Agents